Bluejay Diagnostics, Inc. BJDX 深 滬
等待開盤 11-26 09:30:00 美东时间
1.38
0.000
0.00%
華盛通- 最 高1.4498
- 今 開1.38
- 成交量 5.07万股
- 最 低 1.33
- 昨 收 1.38
- 總市值 206.20万
- 52周最高 10.20
- 市盈率 靜 --
- 換手率 3.39%
- 52周最低 1.235
- 委 比 -39.64%
- 總股本 149.42万
- 歷史最高 50000.00
- 量 比 1.05
- 振 幅 8.68%
- 歷史最低 1.235
- 每 手 1
- 風險率 1.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
11-13 20:06
Bluejay Diagnostics Pushes Forward with 20-Minute Sepsis Test, Reports $3M in Cash, But Needs $20M to Reach FDA Goal
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing near-patient testing solutions for critical care, announced financial results for the quarter ended September
11-10 20:52
Bluejay Diagnostics Advances Sepsis Study with IL-6 Monitoring
Bluejay Diagnostics, Inc. (($BJDX)) announced an update on their ongoing clinic...
10-28 00:53
Bluejay Diagnostics Raises $4M in Private Placement
The latest update is out from Bluejay Diagnostics ( ($BJDX) ). On October 9, 20...
10-14 18:55
Market-Moving News for October 9th
DAL: 6% | Delta Air Lines shares are trading higher after the company reported better-than-expected Q3 financial results and raised FY25 EPS outlook. TELO: 42% | Telomir Pharmaceuticals shares are trading
10-09 19:16
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics, a medical diagnostics company, closed a private placement of 2.25 million shares of common stock and Series F warrants for up to 4.5 million shares, priced at $2.00 per share, raising $4.5 million. The proceeds will support FDA approval efforts, clinical studies, research and development, and general working capital. The offering is under Section 4(a)(2) of the Securities Act and Regulation D. The warrants have an exercise pr...
10-09 19:15
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
Bluejay Diagnostics and SanyoSeiko Co., Ltd. have expanded their partnership, with SanyoSeiko taking on an expanded role in commercializing Bluejay's Symphony platform, a near-patient testing system for critical care. Under the amended agreement, SanyoSeiko will provide end-to-end support for the Symphony platform, including manufacturing redevelopment, supply chain management, and production of analyzers, cartridges, and related components. This...
10-09 10:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock moved upwards by 137.1% to $10...
10-09 01:06
Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?
Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite facing significant losses over the past year.
10-08 15:40
Bluejay Diagnostics Announces Board Leadership Changes
The latest announcement is out from Bluejay Diagnostics ( ($BJDX) ). On August ...
08-16 05:47
